High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: Long-term results

Haematologica

Volumn 94, Issue 1, 2009, Pages 146-148

  Carella, Angelo Michele ^a   Bellei, Monica ^b   Brice, Pauline ^c   Gisselbrecht, Christian ^c   Visani, Giuseppe ^d   Colombat, Philippe ^e   Fabbiano, Francesco ^f   Donelli, Amedea ^b   Luminari, Stefano ^b   Feugier, Pierre ^g   Browett, Peter ^h   Hagberg, Hans ⁱ   Federico, Massimo ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c SAINT LOUIS HOSPITAL   (France)

^d SAN SALVATORE HOSPITAL   (Italy)

^e CHU BRETONNEAU   (France)

^f VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^g UNIVERSITY HOSPITAL OF NANCY   (France)

^h UNIVERSITY OF AUCKLAND   (New Zealand)

ⁱ UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; FOLLOW UP; HODGKIN DISEASE; HUMAN; LETTER; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; TIME SERIES ANALYSIS;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; NEOPLASM STAGING; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 58149250522     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.13484     Document Type: Letter

References (8)

1. Carella AM, Carlier P, Congiu A, Occhini D, Nati S, Santini G, et al. Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol. BMT 1991; 8:99-103.
2. Strauss DJ, Gaynor JJ, Myers J, Merke DP, Caravelli J, Chapman D, et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 1990;8:1173-86.
3. Federico M, Bellei M, Brice P, Brugiatelli M, Nagler A, Gisselbrecht C, et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. EBMT/GISL/ANZLG/SFGM/GELA Intergroup HD01 Trial. J Clin Oncol 2003;21:2320-5.
4. Hasenclever D, Diehl V. International Prognostic factors Project on Advanced Hodgkin's Disease. A prognostic score to predict tumor control in advanced Hodgkin's Disease. N Engl J Med 1998;339:1506-14.
5. André M, Henry-Amar M, Blaise D, Colombat P, Fleury J, Milpied N, et al. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 1998;92:1933-40.
6. Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006;91:475-81.
7. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107:52-9.
8. 18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746-52.